Immunic (IMUX) Stock Price, News & Analysis

Company Overview

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis. A second program, IMU-935, targets the RORγt pathway, with preclinical and early-stage clinical studies designed to assess its potential in treating psoriasis and other inflammatory disorders. Both programs reflect the company’s commitment to advancing therapies that may offer improved efficacy and convenience compared to existing injections or infusions.

Founded in 2008 and headquartered in New York, Immunic maintains research operations in Germany to leverage its European expertise in medicinal chemistry and translational science. This transatlantic footprint supports robust clinical trial activity and enables collaboration with international academic and clinical partners. Over the years, the company has progressed its pipeline through strategic financing rounds and regulatory engagement, culminating in its NASDAQ listing in early 2020.

Under the leadership of Chief Executive Officer Friederike Bertram, M.D., Immunic continues to expand its pipeline and explore additional indications for its platform of oral immunology agents. Guided by a management team experienced in drug development and regulatory affairs, the company aims to bring new therapeutic options to patients living with immune-mediated diseases and certain oncologic conditions.

Key Stats

• Today's Range: $12.35 to $13.28
• 50-Day Range: $12.74 to $16.90
• 52-Week Range: $5.06 to $17.43
• Volume: 405,016 shs
• Average Volume: 230,496 shs
• Market Capitalization: $173.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.25
• Consensus Rating: Buy

Immunic Stock Analysis - MarketRank™

Immunic scored higher than 65% of companies evaluated by MarketBeat, and ranked 256th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Immunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Immunic has a consensus price target of $47.25, representing about 270.9% upside from its current price of $12.74.

Amount of Analyst Coverage

Immunic has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immunic are expected to grow in the coming year, from ($3.71) to ($2.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunic is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunic is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.90% of the float of Immunic has been sold short.

Short Interest Ratio / Days to Cover

Immunic has a short interest ratio ("days to cover") of 7.01.

Change versus previous month

Short interest in Immunic has recently decreased by 10.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunic does not currently pay a dividend.

Dividend Growth

Immunic does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.36

News Sentiment

Immunic has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Immunic this week, compared to 4 articles on an average week.

Search Interest

21 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.

MarketBeat Follows

10 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immunic insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.49% of the stock of Immunic is held by insiders.

Percentage Held by Institutions

51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/08/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IMUX
• CIK: 1280776
• Web: www.immunic-therapeutics.com
• Phone: (332) 255-9818
• Fax: 858-673-6843
• Employees: 70
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Immunic: $47.25
• High Price Target: $130.00
• Low Price Target: $19.00
• Potential Upside/Downside: +270.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$97.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -157.89%
• Return on Assets: -107.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.05
• Quick Ratio: 5.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.55) per share
• Price / Book: -23.16

Miscellaneous

• Outstanding Shares: 13,644,000
• Free Float: 12,895,000
• Market Cap: $173.82 million
• Optionable: Optionable
• Beta: 1.41